Prostate Cancer FAQ
Prostate Cancer FAQ
Medical questions decide what treatment you need; practical questions decide whether you can get it. This page collects what international patients actually ask our team before and during prostate cancer care — cost structure, hospital stay, medicines, records, insurance, follow-up and nutrition. Conceptual questions are answered on the overview page .
Cost and estimates
We quote by item: the surgical fee, hospital bed days, pathology including the grade group reporting, anaesthesia, imaging, and any radiotherapy or systemic treatment as separate lines. Treatment for international patients runs at roughly 30%–50% of comparable care in Europe or the United States. What we do not do is quote a single figure before seeing the file — the difference between low-risk disease managed by surveillance and metastatic disease on continuous systemic treatment is the difference between two very different budgets, and a wrong number helps nobody plan.
The written assessment after records review includes an itemised estimate: the operation or radiotherapy course, the expected hospital nights, staging imaging, and any genetic testing. Where hormone treatment is anticipated, the duration and the cost of the injections are itemised separately, because a one-year or three-year course is a recurring expense rather than a one-off, and it should be planned as such.
Length of stay and recovery
For nerve-sparing robotic or laparoscopic prostatectomy: two to three nights in hospital, a urinary catheter for about a week, and a return to ordinary activity within a few weeks — with light lifting restrictions early on. Radiotherapy runs as daily outpatient treatment over several weeks; stereotactic courses are far shorter, and brachytherapy involves a brief admission or day-case procedure. For patients travelling, the realistic minimum is around two to three weeks in the country for surgery and the first post-operative review.
Two planning points matter more here than in most cancers. Catheter removal and the first continence assessment happen about a week after surgery, so the trip should extend past that point rather than ending at discharge. And where hormone treatment accompanies radiotherapy, the injections continue after the patient goes home — the plan is written so the local clinician can administer them without further interpretation.
Medicines to bring
Bring regular medicines in original packaging with the prescription or a doctor's letter — this includes blood pressure and diabetes medication, anticoagulants, and any hormone treatment already started. If you take an anticoagulant, the peri-operative plan must be agreed before travelling, so bring the recent INR record or the anticoagulant name and dose. Painkillers and post-operative medication are provided by the hospital.
One item specific to this disease: men on androgen deprivation therapy should bring documentation of the agent and the date of the last injection, because the dosing interval matters to how treatment is continued here. And any medication marketed for prostate health — saw palmetto, herbal preparations, supplements — should be declared rather than continued silently, since some interact with treatment and several have no evidence of benefit.
Records to prepare
The file that changes the quality of the assessment, in order of importance:
- The PSA history with dates — a series of values, not only the most recent one
- The biopsy pathology report with the grade group, the number of positive cores and the percentage of pattern 4
- The multiparametric MRI report with the PI-RADS score, plus the images if available
- Any PSMA PET-CT, bone scan or CT already performed
- Any germline genetic result, or the family history that would justify testing
- A medication list and recent blood results, including renal function and testosterone if measured
Two items are missing from most files and both matter disproportionately: the PSA series, because the trend carries what a single value cannot, and the grade group, because many older reports state only a Gleason sum. If the report lacks a grade group, the pathology slides or block can be reviewed here — and where the MRI was reported without a PI-RADS score, a re-read is often worthwhile rather than repeating the scan.
Insurance and payment
The network holds direct-billing agreements with more than 55 international insurers, which means the hospital invoices the insurer directly for covered treatment and you handle only the excess. Coverage for cancer treatment is standard in international policies; what varies is whether specific items fall inside the approved list — PSMA PET-CT, germline genetic testing, and the newer hormonal agents are the usual questions — and that is checked before treatment starts, not after.
Where direct billing does not apply, payment is by deposit with the itemised estimate as the reference, and invoices are issued in a form most insurers accept for reimbursement. Both the estimate and the coverage check happen before travel. One item worth flagging in advance: continuous hormone treatment generates recurring invoices over years, so if reimbursement is involved, agreeing the mechanism up front avoids repeated paperwork later.
Life after treatment
Follow-up after prostate cancer is built around the PSA test, because it is the most sensitive marker of what the disease is doing. After surgery, PSA is typically checked every three to six months initially and should fall to undetectable; after radiotherapy it falls more gradually and a low plateau is expected. Rising values trigger imaging — usually PSMA PET-CT — and salvage treatment, which is far more targeted than it once was.
Two functional threads deserve explicit attention rather than quiet endurance. Continence improves over months for most men after surgery, and pelvic floor physiotherapy started early makes a measurable difference; where it does not resolve, further options exist and should be raised rather than waited out. Sexual function depends on whether the nerve bundles could be preserved, and recovery can be gradual, sometimes over a year or more, with treatments that support it. For men on long-term hormone therapy, the third thread is the body itself — muscle, bone and cardiovascular health — and the follow-up visit should treat exercise, bone density and cardiac risk as part of the plan rather than as separate concerns.
Eating during treatment
Nutrition after prostate surgery is straightforward: a normal diet resumes within a day or two, with attention to fluid intake and to avoiding constipation in the first weeks, since straining affects the healing anastomosis. During pelvic radiotherapy, the priority is bowel comfort — smaller meals more often, adequate fluids, limiting very high-fibre raw vegetables and spice if they aggravate symptoms, and a dietitian's input before the course rather than after weight loss.
Hormone therapy is where nutrition and activity matter most, and the emphasis differs from most cancer treatment: this is not a time for weight loss diets but for preserving muscle. Resistance training combined with adequate protein intake counters the loss of muscle mass and the rise in fat that androgen deprivation causes, and protects bone density alongside vitamin D and calcium. Men on hormone therapy should also have cardiovascular risk factors monitored, because the treatment affects them — which makes this a period where diet and exercise are part of the prescription rather than general advice.